Clindamycin Clinical Applications

Mechanism of Action and Spectrum

Clindamycin inhibits bacterial protein synthesis and suppresses toxin production, making it particularly valuable for treating infections caused by toxin-producing anaerobes 1

The Infectious Diseases Society of America recommends clindamycin for purulent cellulitis at a dose of 300-450 mg PO three times daily for adults 2
Clindamycin provides effective empirical coverage for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in outpatient skin and soft tissue infections, as recommended by the Infectious Diseases Society of America 3
For hospitalized children with complicated skin and soft tissue infections, the Infectious Diseases Society of America recommends clindamycin 10-13 mg/kg/dose IV every 6-8 hours if local resistance rates are low (<10%) 3
The American Academy of Dermatology recommends clindamycin as a topical formulation for inflammatory acne vulgaris, with a standard topical application of a thin film once daily to affected areas 5

The Infectious Diseases Society of America recommends clindamycin 300-450 mg three times daily for adults with skin and soft tissue infections 2
For anaerobic infections, the recommended dose is 900-1800 mg total daily dose divided into 3-4 doses, as suggested by Praxis Medical Insights 1
For children, the Infectious Diseases Society of America recommends clindamycin 10-13 mg/kg/dose every 6-8 hours, not to exceed 40 mg/kg/day 2

The American Academy of Dermatology notes that clindamycin is contraindicated in patients with a history of hypersensitivity to clindamycin or lincomycin 5
The American Academy of Dermatology also notes that clindamycin is contraindicated in patients with a history of regional enteritis or ulcerative colitis 5

The American Academy of Dermatology warns that clindamycin has neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents 5
The American Academy of Dermatology advises against using clindamycin in combination with erythromycin-containing products 5

The American Academy of Dermatology states that the safety and effectiveness of clindamycin have not been established in children under 12 years for topical formulations 5

The Infectious Diseases Society of America recommends incision and drainage as the primary treatment for abscesses, with antibiotics as adjunctive therapy for specific conditions (systemic illness, immunosuppression, extremes of age) 2
Praxis Medical Insights suggests that when treating mixed infections involving both anaerobes and gram-negative bacteria, combination therapy with agents effective against gram-negative organisms is necessary 1
Praxis Medical Insights recommends transitioning from IV to oral therapy when the patient has shown clinical improvement and has been afebrile for 48-72 hours 1